Skip to content

Optimal Management of Extreme Obesity and Severe Knee Osteoarthritis Feasibility Trial

Optimal Management of Extreme Obesity and Severe Knee Osteoarthritis Feasibility Trial

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05120492
Acronym
OMEOSKO
Enrollment
20
Registered
2021-11-15
Start date
2022-04-22
Completion date
2027-07-31
Last updated
2024-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee Osteoarthritis, Morbid Obesity

Keywords

Arthroplasty, Replacement, Knee, Bariatric Surgery

Brief summary

Does weight loss surgery in patients with morbid obesity prior to knee replacement surgery improve outcomes from knee replacement surgery

Detailed description

RCT involving patients who have severe knee osteoarthritis and have a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of 45 to 60 and are randomly assigned to receive dietary and lifestyle counseling for 9 to 13 months followed by total knee replacement (control arm) or sleeve gastrectomy with dietary and lifestyle counseling for 9 to 13 months followed by total knee replacement (treatment arm).

Interventions

PROCEDUREbariatric surgery followed by total knee replacement

The only intervention is the randomization of the priority of the 2 procedures.

Sponsors

Nova Scotia Health Authority
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

severe knee osteoarthritis body-mass index of 45 to 60

Exclusion criteria

previous total replacement of the same knee, a need for bilateral total knee replacement, and knee pain during the previous week that the patient rated at higher than 60 mm on a 100-mm visual-analogue scale. Also,prior bariatric or complex foregut surgery, significant cardiovascular, pulmonary, renal, liver, gastrointestinal, psychiatric disorders, pregnancy, malignancy within last 5 years, anemia, coagulopathy requiring anti-coagulation therapy.

Design outcomes

Primary

MeasureTime frameDescription
Pain, mobility and quality of Life1 yearKnee Injury and Osteoarthritis Outcome Score (KOOS4)

Secondary

MeasureTime frameDescription
EuroQol Group 5-Dimension Self Report Questionnaire (EQ-5D)1 yearassessing quality of life.

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026